Imatinib alone and in combination for chronic myeloid leukemia

被引：75

作者：

Druker, BJ

机构：

来源：

SEMINARS IN HEMATOLOGY | 2003年 / 40卷 / 01期

关键词：

TYROSINE KINASE INHIBITOR; CHRONIC MYELOGENOUS LEUKEMIA; ABL-POSITIVE CELLS; ACUTE LYMPHOBLASTIC-LEUKEMIA; BCR-ABL; ANTILEUKEMIC AGENTS; APOPTOSIS; EFFICACY; STI-571; GROWTH;

D O I：

10.1053/shem.2003.50000

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：50 / 58

页数：9

共 53 条

[1]

Beran M, 1998, CLIN CANCER RES, V4, P1661

[2] High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance [J].

Branford, S ;

Rudzki, Z ;

Walsh, S ;

Grigg, A ;

Arthur, C ;

Taylor, K ;

Herrmann, R ;

Lynch, KP ;

Hughes, TP .

BLOOD, 2002, 99 (09) :3472-3475

[3] Bcr-Abl inhibition as a modality of CML therapeutics [J].

Buchdunger, E ;

Matter, A ;

Druker, BJ .

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2001, 1551 (01) :M11-M18

[4] CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins [J].

Carroll, M ;

OhnoJones, S ;

Tamura, S ;

Buchdunger, E ;

Zimmermann, J ;

Lydon, NB ;

Gilliland, DG ;

Druker, BJ .

BLOOD, 1997, 90 (12) :4947-4952

[5] The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells [J].

Deininger, MWN ;

Goldman, JM ;

Lydon, N ;

Melo, JV .

BLOOD, 1997, 90 (09) :3691-3698

[6] Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors [J].

Demetri, GD ;

von Mehren, M ;

Blanke, CD ;

Van den Abbeele, AD ;

Eisenberg, B ;

Roberts, PJ ;

Heinrich, MC ;

Tuveson, DA ;

Singer, S ;

Janicek, M ;

Fletcher, JA ;

Silverman, SG ;

Silberman, SL ;

Capdeville, R ;

Kiese, B ;

Peng, B ;

Dimitrijevic, S ;

Druker, BJ ;

Corless, C ;

Fletcher, CDM ;

Joensuu, H .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :472-480

[7]

Dorsey JF, 2000, CANCER RES, V60, P3127

[8]

Druker B J, 2001, Hematology Am Soc Hematol Educ Program, P87

[9]

Druker B.J, 2002, P AN M AM SOC CLIN, V21, P1

[10] Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. [J].

Druker, BJ ;

Sawyers, CL ;

Kantarjian, H ;

Resta, DJ ;

Reese, SF ;

Ford, JM ;

Capdeville, R ;

Talpaz, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1038-1042

← 1 2 3 4 5 6 →